PT - JOURNAL ARTICLE AU - Chang, Yeh-Chung AU - Young, Rebecca R. AU - Mavis, Alisha M. AU - Chambers, Eileen T. AU - Kirmani, Sonya AU - Kelly, Matthew S. AU - Kalu, Ibukunoluwa C. AU - Smith, Michael J. AU - Lugo, Debra J. TI - Epstein-Barr Virus DNAemia and Post-Transplant Lymphoproliferative Disorder in Pediatric Solid Organ Transplant Recipients AID - 10.1101/2022.06.04.22275823 DP - 2022 Jan 01 TA - medRxiv PG - 2022.06.04.22275823 4099 - http://medrxiv.org/content/early/2022/06/06/2022.06.04.22275823.short 4100 - http://medrxiv.org/content/early/2022/06/06/2022.06.04.22275823.full AB - Background Pediatric solid organ transplant (SOT) recipients commonly have Epstein-Barr virus (EBV) DNAemia and are at risk of developing post-transplant lymphoproliferative disorder (PTLD). EBV DNAemia has not been analyzed on a continuous scale in this population.Methods All children ≤ 18 years of age who underwent SOT at a single center between January 1, 2007 and July 31, 2018 were included in this retrospective study. Transplant episodes in which PTLD occurred were compared to transplant episodes without PTLD. Multivariable logistic regression was used to identify factors associated with the development of EBV DNAemia and maximum height of EBV DNAemia. A Cox proportional hazards model was used to calculate hazard ratios for time to PTLD.Results Of 275 total transplant recipients and 294 transplant episodes, there were 14 episodes of PTLD. Intestinal and multivisceral transplant were strongly associated with PTLD (p=0.002). Risk factors for the development of EBV DNAemia include donor and recipient positive EBV serologies (p=0.001) and older age (p=0.001). Maximum level of EBV DNAemia was significantly associated with development of PTLD (p<0.0001). Every one log (log10) increase in the maximum level of EBV DNAemia was associated with a more than doubling of the hazard on developing PTLD (HR: 2.18, 95% CI 1.19-3.99).Conclusions Transplant type was strongly associated with development of PTLD in pediatric SOT recipients. EBV serologies and age were associated with the development of EBV DNAemia and height of DNAemia. High levels of EBV DNAemia were strongly associated with an increased hazard of PTLD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Duke University Health System Institutional Review Board of the Duke University School of Medicine gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.